Gilead Clinical Trials

Graphic

Gilead HIV Pipeline

Gilead’s research and development program is focused on what’s next. Shown here is our current pipeline and phases of development.

Graphic

Ongoing Phase 2/3 Clinical Trials for HIV Treatment: CAPELLA and CALIBRATE

Two studies (CAPELLA and CALIBRATE) are currently enrolling participants to evaluate the efficacy and safety of investigational lenacapavir (LEN), a novel capsid inhibitor, for the potential treatment of HIV. LEN is administered as a long-acting subcutaneous injection every 6 months in these studies.

  • CAPELLA is studying LEN as an add-on to a failing regimen in heavily treatment-experienced people living with HIV (PLWH) with multidrug resistance
  • CALIBRATE is studying LEN plus other oral antiretrovirals in treatment-naïve PLWH

Additional information on active sites for these studies can be found on clinicaltrials.gov:

Graphic
Graphic